CFO David Mountcastle Sells 17,196 Shares of PRVA
David Mountcastle, PRVA's CFO, sold shares worth $432,995 in a planned transaction.
Key Points
- David Mountcastle, EVP & CFO of PRVA, sold 17,196 shares on June 26, 2026, for $432,995 at an average price of $25.18.
- On Wednesday, PRVA shares traded near $25.55, with major institutional investors like BlackRock and FMR LLC adjusting their holdings.
- Analysts from Barclays and Canaccord Genuity maintain their ratings, with price targets ranging from $24.00 to $35.00.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 26, 2026, David Mountcastle, the Executive Vice President and Chief Financial Officer of PRVA, sold 17,196 shares of the company. This planned transaction was executed at an average price of $25.18 per share, totaling approximately $432,995.
Other Institutional Activity in PRVA
BlackRock, Inc. increased its position in PRVA by 93,747 shares, bringing its total holdings to 19,057,910 shares worth about $392.0 million. FMR LLC also added 995,493 shares, ending with 13,045,542 shares valued at $268.3 million, marking an 8.3% increase. Durable Capital Partners LP held steady with 12,087,843 shares, valued at $248.6 million. Vanguard Portfolio Management LLC opened a new position with 6,281,542 shares, worth approximately $129.2 million. Rubicon Founders LLC increased its stake by 175,142 shares to 5,948,664, valued at $122.4 million.
Privia Health Group, Inc. Stock Up 24.7%
Shares of PRVA traded near $25.55 on Wednesday. The company, which does not have a meaningful P/E ratio due to profitability data not being available, has a 52-week low of $18.50 and a high of $29.75. Its 50-day moving average is $24.90, while the 200-day moving average is $23.30.
$PRVA stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at Privia Health Group, Inc.
In addition to David Mountcastle's sale, Matthew Shawn Morris conducted multiple transactions on June 29, 2026. Morris sold 63,212 shares at $25.33 in a planned transaction and also bought shares on the same day at a nominal price of $2.00 per share.
Analysts Set New Price Targets
On May 26, 2026, Barclays maintained a 'hold' rating on PRVA with a price target of $24.00. Earlier, on May 8, 2026, Canaccord Genuity maintained a 'buy' rating with a target of $34.00. The consensus among analysts is a 'buy' rating, with an average price target of $30.50 based on multiple opinions.
About PRVA
PRVA operates in the healthcare sector, focusing on providing services and solutions to enhance the efficiency and effectiveness of healthcare delivery. The company is headquartered in the United States and works with a range of clients to improve patient outcomes through innovative approaches.
Bottom Line
David Mountcastle's recent sale of shares is part of a planned transaction, reflecting routine insider activity. Investors often watch such moves for insights into executive confidence. It's important to note that these insider transactions and institutional holdings provide snapshots of past actions and may not represent current positions.
Get Privia Health Group, Inc. alerts
New 13F filings, insider trades, and analyst moves on $PRVA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.